NCT06392074View on ClinicalTrials.gov

A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders

PHASE1CompletedINTERVENTIONAL

Enrollment

141

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

May 12, 2025

Study Completion Date

May 12, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

MB04

Subcutaneous injection

DRUG

US License Enbrel

Subcutaneous injection

DRUG

EU Source Enbrel

Subcutaneous injection

Trial Locations (1)

9728 NZ

ICON Clinical Research Unit, Groningen

All Listed Sponsors

lead

mAbxience Research S.L.

INDUSTRY

NCT06392074 - A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders | Biotech Hunter | Biotech Hunter